sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment
Ying Huang(Nanjing Drum Tower Hospital), Baorui Liu(Nanjing University of Chinese Medicine)
Cited by 21
Related Papers
iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
|Nature Communications|2019|125
Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy
|Nature Communications|2022|102
Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy
|Oncology Reports|2017|42
Enhancement of radiotherapy efficacy by miR-200c-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer cells
|International Journal of Nanomedicine|2014|37